Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)

5.22
Delayed Data
As of Sep 23
 -0.28 / -5.09%
Today’s Change
3.50
Today|||52-Week Range
10.20
-31.41%
Year-to-Date
5 Biotech Stocks to Watch as Interest in NASH Increases
Sep 22 / Zacks.com - Paid Partner Content
These Biotech Names Are on My Radar
Sep 20 / TheStreet.com - Paid Partner Content
Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain
Sep 21 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close5.50
Today’s open5.77
Day’s range5.15 - 5.77
Volume737,114
Average volume (3 months)58,243
Market cap$58.0M
Dividend yield--
Data as of 3:59pm ET, 09/23/2016

Growth & Valuation

Earnings growth (last year)-9.09%
Earnings growth (this year)-50.42%
Earnings growth (next 5 years)--
Revenue growth (last year)--
P/E ratio--
Price/Sales--
Price/Book2.69

Competitors

 Today’s
change
Today’s
% change
OCRXOcera Therapeutics I...+0.02+0.76%
CASICASI Pharmaceuticals...+0.06+5.31%
PTNPalatin Technologies...+0.05+8.67%
NWBONorthwest Biotherape...-0.02-3.55%
Data as of 4:02pm ET, 09/23/2016

Financials

Next reporting dateNovember 9, 2016
EPS forecast (this quarter)-$0.37
Annual revenue (last year)$0.00
Annual profit (last year)-$10.6M
Net profit margin--

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, CEO &
Class II Director
Allen Baharaff
Chief Financial Officer
Josh Blacher
Corporate headquarters
Tel Aviv, Tel Aviv

Forecasts

Search for Jobs